| 1) tors in modulating central aspects of the disease. |
| 2) avirus (SARS-CoV-2) which causes COVID-19 disease. |
| 3) virus (SARS-CoV-2), which causes COVID-19 disease. |
| 4) arrier integrity can be promoted to limit disease. |
| 5) ed with increasing age and cardiovascular disease. |
| 6) uch as rheumatoid arthritis and Crohn’s disease. |
| 7) lationship between NOU and cardiovascular disease. |
| 8) omes for most aspects associated with the disease. |
| 9) no confirmed treatment or vaccine for the disease. |
| 10) utic strategies to treat this devastating disease. |
| 11) the review goal was broadened to chronic disease. |
| 12) rs for atherosclerosis and cardiovascular disease. |
| 13) herbicide paraquat (PQ) with Parkinson's disease. |
| 14) mammalian and human early embryo loss and disease. |
| 15) uate the multi-system involvement of this disease. |
| 16) reatment of patients with severe COVID-19 disease. |
| 17) rain areas, at different ages, and during disease. |
| 18) isk of mortality in patients with chronic disease. |
| 19) type 2 diabetes mellitus and Alzheimer's disease. |
| 20) t fit all" in the treatment of autoimmune disease. |
| 21) the mechanism of APOL1 associated kidney disease. |
| 22) stinal organ development, physiology, and disease. |
| 23) ndrial import machinery involved in heart disease. |
| 24) cation, and current treatments of the PAH disease. |
| 25) effects on all molecular subtypes of the disease. |
| 26) e globin genes, collectively known as HbM disease. |
| 27) arious diseases, including cardiovascular disease. |
| 28) induces cytokine secretion during retinal disease. |
| 29) tamin D may affect the development of the disease. |
| 30) iduals, ~50% present with severe allergic disease. |
| 31) ion in males even after recovery from the disease. |
| 32) as regulatory cells during chronic liver disease. |
| 33) ment and progression of neurodegenerative disease. |
| |